Project portfolio

2022 Q3 Portfolio ENG-b

  1. Partner with Eisai for lecanemab for treatment of Alzheimer’s disease since 2007. Eisai entered partnership with Biogen regarding BAN2401 (lecanemab) in 2014
  2. Mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease
  3. Normal cognitive function with intermediate or elevated levels of amyloid in the brain
  4. Dementia and cognitive impairment associated with Down’s syndrome and with traumatic brain injury

BioArctic’s portfolio has projects in several focus areas and in various phases from discovery through clinical development. Project portfolio as of January 11, 2023.